The Yukon government has made the decision to fully fund flash glucose monitors (Flash GMs) for those 18 years of age and older with type 1 diabetes (T1D) starting on October 1st.
As 2021 draws near, we move closer to an important milestone that changed and aided the type 1 diabetes (T1D) community in an enormous way – the 100th year of insulin.
There’s good news for pumpers in BC! BC Pharmacare has added YpsoPump by YpsoMed to its Tier 1 list of approved insulin pumps. BC residents with type 1 diabetes of all ages can now choose between the Omnipod by Insulet or the YpsoPump under the province’s pump program.
JDRF’s attention has been focused on Canada’s west coast increasingly as the BC government inches closer to a decision on whether or not to cover continuous glucose monitoring (CGM) and flash glucose monitoring (FGM) systems. BC Pharmacare commissioned a health technology assessment on these technologies more than a year ago but the results have yet to be released.
A recent increase in type 1 diabetes (T1D) diagnoses in children under 18 in some hospitals in north-west London, UK, has triggered news stories that COVID-19 could cause the disease in children. But experts have stressed that the locally reported increase in diagnoses is not yet clearly linked to the pandemic.
As students across Canada get ready to head back to school—some after nearly 6 months of being away—parents have many questions. The first is usually, “Is it safe to send my child back to school during this pandemic?”
Here are some things to consider when making a decision about sending your child with type 1 diabetes (T1D) back to school.
Kidney disease remains one of the leading complications of diabetes, including the need for dialysis or kidney transplant. This led to the Preventing Early Renal Loss in Diabetes (PERL) trial, a joint initiative between investigators across North America and Denmark.
With visits to healthcare professionals (HCPs) now mostly virtual, tele-health and Zoom meetings now the norm, there comes a heavier reliance on self-monitoring.
We are incredibly grateful to our partners, and the entire T1D community for their commitment and support as we work together to move type 1 diabetes research forward faster than ever.
This month, we wanted to recognize some of our amazing monthly donors and thank them for their support. Their stories will help you understand why they’re In to End Diabetes.
Your stories make all the difference.
Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two years—the onset of type 1 diabetes (T1D) in participants with a high risk of developing the disease. This was the first ever study in humans to show a delay in the onset of T1D. But it doesn’t stop there. JDRF has very promising updated results.
